DOUGLAS REED: Open Payments
NPI 1801830443 · WILLIAMSPORT, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$528 in 34 payments from 9 companies in 2025. Trend: 2023 $1,325 · 2024 $907 · 2025 $528
Food & beverage: $528
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $143 |
| Teva Pharmaceuticals USA, Inc. | 6 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| ABBVIE INC. | 4 | $60 |
| Neurocrine BioSciences, Inc. | 3 | $56 |
| Alkermes, Inc. | 3 | $45 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: CAPLYTA, UZEDY, VRAYLAR, INGREZZA, ABILIFY MAINTENA, LYBALVI, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across PA — which companies pay providers there.
